We have sought to define the relationship between the proportion of marrow metaphases
showing the Philadelphia chromosome (Ph) and levels of BCR‐ABL mRNA assessed by …

Detection of BCR-ABL transcripts in chronic myeloid leukaemia (CML) is used to confirm the
diagnosis and to monitor residual disease. Quantitative techniques are required to predict …

The level of BCR-ABL1 reached after treatment with tyrosine kinase inhibitors is an effective
marker of the therapeutic response and a good survival predictor in chronic myeloid …

The Philadelphia chromosome of chronic myelogenous leukemia (CML) patients is caused
by a translocation of the c-abl gene from chromosome 9 to the breakpoint cluster region (bcr) …

We developed and extensively validated a real-time PCR assay for the quantitation of bcr-
abl to determine residual disease in patients with chronic myelogenous leukemia. This …

Individualized PCR strategies hamper comparability of molecular results between different
laboratories in several fields of medicine. To harmonize BCR-ABL mRNA quantification an …

Background The monitoring of BCR-ABL transcript levels by real-time quantitative
polymerase chain reaction (RT-qPCR) has become important to assess minimal residual …

Real-time RT-PCR has great advantages for estimating transcript levels in a variety of
situations. These include relative rapid assay times (hours), reliability and ease of …

In patients with chronic myeloid leukemia (CML), the leukemic (BCR-ABL+/Ph+) clone
typically includes cells belonging to all of the myeloid lineages and frequently some B cells …

Abstract The Philadelphia chromosome (Ph) is found in most chronic myelogenous
leukemia (CML) patients. The bcr-abl oncoprotein (P210 or PI85), the product of the fused …